Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

HIV is currently the only disease carrying a felony charge if someone knowingly transmits it to another person. The Senate ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.

Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant outcomes, researchers said at the Conference on Retroviruses and Opportunistic ...